|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ChiCTR |
|
Last refreshed on:
|
18 April 2017 |
|
Main ID: |
ChiCTR-IPR-15006695 |
|
Date of registration:
|
2015-07-05 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Adjunctive with intravitreal injection of ranibizumab before Ahmed glaucoma valve implantation in the treatment of neovascular glaucoma: a prospective randomized controlled study
|
|
Scientific title:
|
Adjunctive with intravitreal injection of ranibizumab before Ahmed glaucoma valve implantation in the treatment of neovascular glaucoma: a prospective randomized controlled study |
|
Date of first enrolment:
|
2016-01-01 |
|
Target sample size:
|
ranibizumab group:46;bevacizumab group:46; |
|
Recruitment status: |
Temporary halt |
|
URL:
|
http://www.chictr.org.cn/showproj.aspx?proj=11369 |
|
Study type:
|
Interventional study |
|
Study design:
|
Randomized parallel controlled trial
|
|
Phase:
|
Post-market
|
|
|
Countries of recruitment
|
|
China
| | | | | | | |
|
Contacts
|
|
Name:
|
Minwen Zhou
|
|
Address:
|
100 Haining Road, Shanghai
210060
|
|
Telephone:
|
+86 18022371980 |
|
Email:
|
zmw8008@163.com |
|
Affiliation:
|
|
|
|
Name:
|
Minwen Zhou
|
|
Address:
|
100 Haining Road, Shanghai
210060
|
|
Telephone:
|
+86 18022371980 |
|
Email:
|
zmw8008@163.com |
|
Affiliation:
|
Shanghai First People's Hospital |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: 1) provide informed consent and can follow up;
2) All patients older than 18 years;
3) Patients who presented with neovascularization on the iris and the anterior chamber angle and had an established diagnosis of NVG;
4) Patients with uncontrolled IOP of 22mm Hg or more on maximally tolerated medical therapy.
Exclusion criteria: 1) Patients unwilling or unable to provide informed consent to participate in the study or to adhere to the study requirements, including implant randomization and required follow-up visits, were excluded;
2) NVG secondary to intraocular tumors or uveitis;
3) earlier cyclodestructive procedure, scleral buckle procedure, previous glaucoma drainage device implantation or silicone oil surgery;
4) pregnancy;
5) Patients with no light perception.
Age minimum:
18
Age maximum:
65
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
neovascular glaucoma
|
|
Intervention(s)
|
|
ranibizumab group:adjunctive intravitreal ranibizumab injection with Ahmed Glaucoma Valve implantation;bevacizumab group:adjunctive intravitreal bevacizumab injection with Ahmed Glaucoma Valve implantation;
|
|
Primary Outcome(s)
|
|
Intraocular pressure;
|
|
Secondary Outcome(s)
|
|
success rate;glaucoma medications reduction;visual acuity;Complication;
|
|
Source(s) of Monetary Support
|
|
Shanghai Science and Technology Innovation action medical key Program (1341195400)
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|